Abstract
Chronic acquired tubulointerstitial disease encompasses a heterogeneous collection of causes of kidney injury. Although there are a number of uncommon and/or regionally specific diagnoses which present in this category, there is also an inadequately defined and, as yet, poorly understood syndrome responsible for a substantial burden of kidney disease morbidity and mortality in low- and middle-income countries. Given the attributes of the renal tubule, chronic injury is most typically due to long-term exogenous toxin exposure, although metabolic, infectious and autoimmune causes are also well described. Chronic acquired tubulointerstitial disease typically presents without clear symptoms, and proteinuria, haematuria and hypertension are often absent, making identification challenging except through estimates of kidney function using serum biomarkers. Renal biopsy will demonstrate tubulointerstitial fibrosis, but the underlying cause is usually ascertained from the clinical history. Although specific therapy may be indicated in certain cases, reduction in exposure to environmental factors is likely to be the key intervention to reduce the impact of these diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bamias G, Boletis J. Balkan nephropathy: evolution of our knowledge. Am J Kidney Dis. 2008;52(3):606–16.
Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968–1979). N Engl J Med. 1983;308(7):357–62.
Peraza S, et al. Decreased kidney function among agricultural workers in El Salvador. Am J Kidney Dis. 2012;59(4):531–40.
Iwagami M, et al. Severe mental illness and chronic kidney disease: a cross-sectional study in the United Kingdom. Clin Epidemiol. 2018;10:421–9.
Close H, et al. Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS One. 2014;9(3):e90169.
Kessing LV, et al. Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study. JAMA Psychiat. 2015;72(12):1182–91.
Bendz H, et al. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int. 2010;77(3):219–24.
Curhan GC, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164(14):1519–24.
Fored CM, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001;345(25):1801–8.
Becker CG, et al. Nephrotic syndrome after contact with mercury. A report of five cases, three after the use of ammoniated mercury ointment. Arch Intern Med. 1962;110:178–86.
Gerhardt RE, et al. Chronic renal insufficiency from cortical necrosis induced by arsenic poisoning. Arch Intern Med. 1978;138(8):1267–9.
Katsuma A, et al. Acute renal failure following exposure to metallic mercury. Clin Nephrol. 2014;82(1):73–6.
Sathe K, Ali U, Ohri A. Acute renal failure secondary to ingestion of ayurvedic medicine containing mercury. Indian J Nephrol. 2013;23(4):301–3.
Inglis JA, Henderson DA, Emmerson BT. The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol. 1978;124(2):65–76.
Emmerson BT. “Ouch-ouch” disease: the osteomalacia of cadmium nephropathy. Ann Intern Med. 1970;73(5):854–5.
Nogawa K, Kido T. Biological monitoring of cadmium exposure in itai-itai disease epidemiology. Int Arch Occup Environ Health. 1993;65(1 Suppl):S43–6.
Hsu LI, et al. Arsenic exposure from drinking water and the incidence of CKD in low to moderate exposed areas of Taiwan: a 14-year prospective study. Am J Kidney Dis. 2017;70(6):787–97.
Hellstrom L, et al. Cadmium exposure and end-stage renal disease. Am J Kidney Dis. 2001;38(5):1001–8.
Sommar JN, et al. End-stage renal disease and low level exposure to lead, cadmium and mercury; a population-based, prospective nested case-referent study in Sweden. Environ Health. 2013;12:9.
Mengs U. Acute toxicity of aristolochic acid in rodents. Arch Toxicol. 1987;59(5):328–31.
Yang CS, et al. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis. 2000;35(2):313–8.
Nortier JL, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686–92.
Gokmen MR, et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med. 2013;158(6):469–77.
Malir F, et al. Ochratoxin A: 50 years of research. Toxins (Basel). 2016;8(7):191.
Zaied C, et al. Presence of ochratoxin A in Tunisian blood nephropathy patients. Exposure level to OTA. Exp Toxicol Pathol. 2011;63(7–8):613–8.
Abbara A, Davidson RN, Medscape. Etiology and management of genitourinary tuberculosis. Nat Rev Urol. 2011;8(12):678–88.
Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol. 2003;23(5):486–99.
Bouquegneau A, et al. Anorexia nervosa and the kidney. Am J Kidney Dis. 2012;60(2):299–307.
Zipfel S, et al. Long-term prognosis in anorexia nervosa: lessons from a 21-year follow-up study. Lancet. 2000;355(9205):721–2.
Delanaye P, et al. Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa. Nephron Clin Pract. 2008;110(3):c158–63.
Li L, et al. Ileostomy creation in colorectal cancer surgery: risk of acute kidney injury and chronic kidney disease. J Surg Res. 2017;210:204–12.
Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. Am J Kidney Dis. 2014;63(3):506–20.
Jayasumana C, et al. Chronic interstitial nephritis in agricultural communities: a worldwide epidemic with social, occupational and environmental determinants. Nephrol Dial Transplant. 2017;32(2):234–41.
Ball S, et al. Why is there so much end-stage renal failure of undetermined cause in UK Indo-Asians? QJM. 2001;94(4):187–93.
Cohen J. Mesoamerica’s mystery killer. Science. 2014;344(6180):143–7.
Gonzalez-Quiroz M, et al. Decline in kidney function among apparently healthy young adults at risk of Mesoamerican nephropathy. J Am Soc Nephrol. 2018.
Wijkstrom J, et al. Morphological and clinical findings in Sri Lankan patients with chronic kidney disease of unknown cause (CKDu): similarities and differences with Mesoamerican Nephropathy. PLoS One. 2018;13(3):e0193056.
Wijkstrom J, et al. Clinical and pathological characterization of Mesoamerican nephropathy: a new kidney disease in Central America. Am J Kidney Dis. 2013;62(5):908–18.
Further Reading/Guidelines
Bipolar disorder: assessment and management 2014 NICE: https://www.nice.org.uk/guidance/cg185.
British Thoracic Society: guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease: https://www.brit-thoracic.org.uk/document-library/clinical-information/tuberculosis/tb-guidelines/guidelines-in-adult-patients-with-tuberculosis-and-chronic-kidney-disease/.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hendra, H., Harber, M., Caplin, B. (2022). Acquired Chronic Tubulointerstitial Nephritis. In: Harber, M. (eds) Primer on Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-76419-7_33
Download citation
DOI: https://doi.org/10.1007/978-3-030-76419-7_33
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-76418-0
Online ISBN: 978-3-030-76419-7
eBook Packages: MedicineMedicine (R0)